305 results on '"Mitlak, Bruce"'
Search Results
52. Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials
53. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
54. Update in Endocrinology
55. OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
56. Abstract #184 Effect of Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
57. OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
58. Effects of Raloxifene in Postmenopausal Women
59. Parathyroid hormone as a therapeutic agent
60. Treatment‐Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained.
61. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
62. Abstract #531 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
63. Abstract #530 Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women with Osteoporosis
64. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
65. Chapter 17 - Pharmaceutical Treatments of Osteoporosis
66. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
67. The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
68. A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
69. REGIONAL MYOCARDIAL PERFUSION MEASURED BY HYDROGEN WASHOUT
70. Bone mineral measurements by DXA in animals
71. Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density
72. Long-term raloxifene for postmenopausal osteoporosis
73. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA
74. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
75. Effect of Raloxifene on All-cause Mortality
76. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
77. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat
78. Asymptomatic primary hyperparathyroidism
79. Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats
80. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability
81. Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
82. Osteosarcoma and Teriparatide?
83. Comments on Initial experience with teriparatide in the United States
84. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
85. Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science
86. Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment
87. Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure
88. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis
89. Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk With Raloxifene Therapy
90. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis
91. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
92. Endometrial Response to Raloxifene Compared with Placebo, Cyclical Hormone Replacement Therapy, and Unopposed Estrogen in Postmenopausal Women
93. Comment on Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys
94. Clinically favorable effects of raloxifene on bone mineral density and serum lipids: population assessment via bivariate analysis
95. Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
96. P-84. Endometrial Effects of Raloxifene Assessed by Bleeding Rates, Ultrasonography, and Biopsy
97. In Search of Optimal Long-Term Female Hormone Replacement: The Potential of Selective Estrogen Receptor Modulators
98. The effect of systemically administered PDGF‐BB on the rodent skeleton
99. Accuracy, precision, and utility of spine and whole-skeleton mineral measurements by dxa in rats
100. Is Diabetes Mellitus a Heart Disease Equivalent in Women?: Results From an International Study of Postmenopausal Women in the Raloxifene Use for the Heart (RUTH) Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.